Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

Fizazi K, Saad F, Alonso-Gordoa T, Żurawski B, Barthélémy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK

Open source

DOI: 10.1016/s1470-2045(25)00566-2
Published: 2026 Jan
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00566-2,
  title = {Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.},
  author = {Fizazi K and Saad F and Alonso-Gordoa T and Żurawski B and Barthélémy P and Voog E and Javier Cutuli H and Buchler T and Ye D and Castellano D and Kwiatkowski M and Arslan C and Richardet M and Alifrangis C and Goh JC and Vianna K and Han W and Hatano K and Todenhöfer T and Retz M and Srivastava A and Jin C and Gupta S and Trandafirescu G and Campos A and Lee CW and van Kooten Losio M and Subudhi SK},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00566-2},
  url = {https://doi.org/10.1016/s1470-2045(25)00566-2}
}

RIS

TY  - JOUR
TI  - Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
AU  - Fizazi K
AU  - Saad F
AU  - Alonso-Gordoa T
AU  - Żurawski B
AU  - Barthélémy P
AU  - Voog E
AU  - Javier Cutuli H
AU  - Buchler T
AU  - Ye D
AU  - Castellano D
AU  - Kwiatkowski M
AU  - Arslan C
AU  - Richardet M
AU  - Alifrangis C
AU  - Goh JC
AU  - Vianna K
AU  - Han W
AU  - Hatano K
AU  - Todenhöfer T
AU  - Retz M
AU  - Srivastava A
AU  - Jin C
AU  - Gupta S
AU  - Trandafirescu G
AU  - Campos A
AU  - Lee CW
AU  - van Kooten Losio M
AU  - Subudhi SK
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00566-2
UR  - https://doi.org/10.1016/s1470-2045(25)00566-2
ER  -

APA

K, F., F, S., T, A., B, Ż., P, B., E, V., H, J. C., T, B., D, Y., D, C., M, K., C, A., M, R., C, A., JC, G., K, V., W, H., K, H., T, T., M, R., A, S., C, J., S, G., G, T., A, C., CW, L., M, V. K. L., & SK, S. (2026). Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00566-2

Source records

pubmed · retrieved 2026-09-26T13:32:33.360Z